Tanovea® (rabacfosadine for injection) support

We are motivated to support your commitment to provide your canine lymphoma patients with high quality care. The tools and materials on this page provide a wealth of useful resources to guide your success when choosing Tanovea.


 Access more information on Tanovea:

Product detailer

Abbreviated product detailer

Client information sheet

Dosage and Administration summary

Product label

CSTD instructional video

Pivotal study

INDICATION: Tanovea is indicated for the treatment of lymphoma in dogs.


IMPORTANT SAFETY INFORMATION: Tanovea is not for use in humans.  Keep out of reach of children.  Do not come into direct contact with Tanovea.  Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment.  Rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility.  Pregnant women, those who may become pregnant, and nursing women should not handle, prepare or administer the product.  Tanovea is associated with life-threatening or fatal pulmonary fibrosis.  Monitoring for signs of pulmonary dysfunction is recommended.  Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding.  Tanovea is associated with dermatopathies which can worsen with subsequent treatment; careful monitoring is recommended.  Tanovea can cause neutropenia with nadir around seven days post-treatment.  Dogs should be frequently monitored for evidence of neutropenia during treatment.  Most common adverse reactions included diarrhea, decreased appetite, emesis, lethargy, weight loss and neutropenia. 

Please see Tanovea product label for full Prescribing Information.


Tanovea, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2021 Elanco or its affiliates.

PM-US-21-2384(2)